Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|CALGB-70301||CALGB||Quality of Life; Employment; and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3 Positive Axillary Lymph Nodes: Companion to CALGB 40101||Adult CIRB - Late Phase Emphasis||Completed|
|NRG-GY007||NRG||A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian; Fallopian Tube; or Primary Peritoneal Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1404||SWOG||A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0819||SWOG||A Randomized; Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1933||SWOG||A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status||Adult CIRB - Late Phase Emphasis||Available to Open|
|E1302||ECOG||Phase III Randomized; Placebo-Controlled Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa; Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|NRG-BR002||NRG||A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-55||NSABP||A Randomised; Double-blind; Parallel group; Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|RTOG-0412-SWOG-S0332||RTOG||Phase III Randomized Trial of Preoperative Chemotherapy Versus Preoperative Concurrent Chemotherapy and Thoracic Radiotherapy Followed by Surgical Resection and Consolidation Chemotherapy in Favorable Prognosis Patients With Stage IIIA (N2) Non-Small Cell Lung Cancer||Adult CIRB - Late Phase Emphasis||Completed|
|S0205||SWOG||A Phase III Randomized Open-Label Study Comparing Gemcitabine Plus Cetuximab (IMC-C225) Versus Gemcitabine as First-Line Therapy of Patients with Advanced Pancreas Cancer||Adult CIRB - Late Phase Emphasis||Completed|